caa a22 4500 475748433 CHVBK 20180406123520.0 cr unu---uuuuu 170329e20000701xx s 000 0 eng 10.1023/A:1006663519132 doi (NATIONALLICENCE)springer-10.1023/A:1006663519132 Prevention of Systemic Lupus Erythematosus-Like Disease in (NZBxNZW)F1 Mice by Treating with CDR1- and CDR3-Based Peptides of a Pathogenic Autoantibody [Elektronische Daten] [Eran Eilat, Heidy Zinger, Abraham Nyska, Edna Mozes] Two peptides based on the complementarity-determining regions (CDR) of a pathogenic murine anti-DNA antibody were employed in an attempt to prevent the spontaneous systemic lupus erythematosus (SLE)-like disease of (NZBxNZW)F1 mice. Female mice, at the age of 2 months, were injected with either the CDR1- or the CDR3-based peptides (pCDR1, pCDR3) subcutaneously or intravenously in aqueous solution for a total of 8-10 treatments. A reduction was observed in the total and pathogenic IgG2a and IgG3 anti-DNA antibody titers in the CDR-treated groups. Treatment reduced the number of mice that developed proteinuria and immune complex deposits in their kidneys. The severity of renal pathology was significantly reduced in the pCDR3 (P < 0.02) and pCDR1 (P ≤ 0.05) treated mice. Thus, both CDR-based peptides administered in aqueous solution were capable of preventing the SLE-like disease in (NZBxNZW)F1 mice, although the beneficial effects of pCDR3 appeared to be more pronounced than those of pCDR1 in the treated mice. Plenum Publishing Corporation, 2000 SLE-like models nationallicence (NZBxNZW)F1 mice nationallicence CDR-based peptide nationallicence immunomodulation nationallicence disease prevention nationallicence Eilat Eran Department of Immunology, The Weizmann Institute of Science, 76100, Rehovot, Israel aut Zinger Heidy Department of Immunology, The Weizmann Institute of Science, 76100, Rehovot, Israel aut Nyska Abraham National Institute of Environmental Health Sciences, Research Triangle Park, 27709-9939, North Carolina aut Mozes Edna Department of Immunology, The Weizmann Institute of Science, 76100, Rehovot, Israel aut Journal of Clinical Immunology Kluwer Academic Publishers-Plenum Publishers 20/4(2000-07-01), 268-278 0271-9142 20:4<268 2000 20 10875 https://doi.org/10.1023/A:1006663519132 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1006663519132 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Eilat Eran Department of Immunology, The Weizmann Institute of Science, 76100, Rehovot, Israel aut NATIONALLICENCE 700 1- Zinger Heidy Department of Immunology, The Weizmann Institute of Science, 76100, Rehovot, Israel aut NATIONALLICENCE 700 1- Nyska Abraham National Institute of Environmental Health Sciences, Research Triangle Park, 27709-9939, North Carolina aut NATIONALLICENCE 700 1- Mozes Edna Department of Immunology, The Weizmann Institute of Science, 76100, Rehovot, Israel aut NATIONALLICENCE 773 0- Journal of Clinical Immunology Kluwer Academic Publishers-Plenum Publishers 20/4(2000-07-01), 268-278 0271-9142 20:4<268 2000 20 10875 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer